Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial
about
Genetics and biology of pancreatic ductal adenocarcinomaGenetic factors affecting patient responses to pancreatic cancer treatmentEmerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cellsImmunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18.LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer.Immunotherapy for pancreatic cancer.Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.Extraordinary response of metastatic pancreatic cancer to apatinib after failed chemotherapy: A case report and literature review.Anti-proliferative and pro-apoptotic effects induced by simultaneous inactivation of HER1 and HER2 through endogenous polyclonal antibodies.Emerging trends in the immunotherapy of pancreatic cancer.The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities.Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review.Chemotherapy in Pancreatic Cancer: A Systematic Review
P2860
Q26765438-88329B5C-D719-45AF-9780-5B3CC508A86FQ28075293-AD4D45C2-2346-4B9B-A7CF-8A275873570EQ33833475-294A1367-4CFA-4925-955C-192B9C17BEF3Q36797398-F1CF7489-D4D8-4180-9C42-B4973F42FFF4Q37578368-4CC9EA79-98B5-41AF-BA05-71E81C66CD67Q38722325-3048629B-FBA1-4EC2-A16D-14B87306B466Q39204274-6421BEA0-C0DC-4616-85FB-B73AD7A290F0Q45771543-E13AC669-A02C-4165-873F-E64FACD4A192Q47111722-DBC86EE8-FBDE-4B35-B287-8041BB12A973Q47248817-69573A23-BE90-49B5-A92F-D4A6A7E7957BQ48098689-528A3DE2-B0FF-4784-8835-DEC5345EB637Q54974100-41E06198-FD48-4C78-860B-EC26D264CBA9Q57824846-E66782EC-5203-4C9E-9A0D-F66521882034
P2860
Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Dual targeting of HER1/EGFR an ...... f the "THERAPY"phase 1-2 trial
@ast
Dual targeting of HER1/EGFR an ...... f the "THERAPY"phase 1-2 trial
@en
type
label
Dual targeting of HER1/EGFR an ...... f the "THERAPY"phase 1-2 trial
@ast
Dual targeting of HER1/EGFR an ...... f the "THERAPY"phase 1-2 trial
@en
prefLabel
Dual targeting of HER1/EGFR an ...... f the "THERAPY"phase 1-2 trial
@ast
Dual targeting of HER1/EGFR an ...... f the "THERAPY"phase 1-2 trial
@en
P2093
P2860
P921
P356
P1433
P1476
Dual targeting of HER1/EGFR an ...... f the "THERAPY"phase 1-2 trial
@en
P2093
André Pèlegrin
Bruno Robert
Caroline Mollevi
Christel Larbouret
David Azria
Denis Smith
Emmanuelle Samalin
Eric Assenat
Evelyne Crapez
Fabienne Portales
P2860
P304
12796-12808
P356
10.18632/ONCOTARGET.3473
P407
P577
2015-05-01T00:00:00Z